Despite the important advances that have enabled better stroke prevention in atrial fibrillation (AF) and more effective maintenance of sinus rhythm over the past decades, a large unmet need to improve the prevention and treatment of AF remains. Mortality for AF remains at 3.5% per year, and death is often experienced as sudden death or as a result of heart failure. Each year, approximately 20% of patients with AF need to be hospitalized, and stroke occurs in 1.5% of patients with AF who are receiving anticoagulant drugs. Furthermore, more than half of the patients with AF are symptomatic despite adequate anticoagulation and rate control. In view of the projected increase in the incidence and prevalence of AF, as well as the substantial burden of death and disability that is still associated with this condition, the status quo is unacceptable.

Current management of patients with AF comprises treatment of the accompanying cardiovascular conditions, oral anticoagulation, rate control — with medications that slow atrioventricular nodal recovery or, rarely, with atrioventricular nodal ablation — and rhythm-control therapy with antiarrhythmic drugs, electrical cardioversion, catheter ablation or, at times, AF surgery. Unfortunately, most of these current approaches are disconnected from our understanding of the major mechanisms that cause AF.
Selective-pathophysiological mechanisms
- Atrial fibrosis
- Abnormal Ca\(^{2+}\) homeostasis
- Ion-channel dysfunction (genetic or acquired)
- Autonomic dysfunction
- Increased oxidative stress
- microRNA-mediated dysregulation
- Paracrine fat-cell activity

Current management strategies
- Therapy of concomitant conditions in all patients
- Anticoagulation stratified by stroke risk factors
- Rate control in all patients, titrated to rate
- Rhythm control in symptomatic patients, partially based on AF duration or AF pattern

Box 1 | Disconnect between known mechanism of AF and management
At present, a disconnect exists between the known mechanisms of atrial fibrillation (AF), and the current management of AF, which is based on a useful, but weak, estimation scheme of the risk of stroke and on AF duration and symptoms (see the figure).

known pathophysiological mechanisms

Current management strategies

disconnect

Guidance through AF characterization
In recognition of the current shortfalls in AF management, several research groups and consensus panels have proposed methods and approaches for improved characterization of the causes of AF in patients. Some groups have recommended the use of cardiac MRI-detected left atrial delayed gadolinium enhancement \(^{37-39}\) for the identification of patients in whom AF is likely to recur after catheter ablation \(^{39-41}\), although an external validation of the feasibility of this technique is needed \(^{42}\). The CHARGE AF consortium identified a set of clinical parameters and biomarkers that could be used to predict AF incidence during follow-up, but did not provide information on the most appropriate prevention or therapy approach \(^{43}\). Similarly, the CHADS\(_2\)S\(_2\)T2 score predicts new-onset AF incidence \(^{44}\), but does not add information on the causes or the mechanisms involved. Delegates at the 4\(^{th}\) AFNET/EHRA consensus conference proposed a classification of AF that reflected the different disease mechanisms. The proposed AF types were: mono-genic AF, focally induced AF, postoperative AF, valvular AF, AF in the elderly, polygenic AF, and unclassified AF \(^{32-35}\). Unfortunately, however, prospective validation of such a classification is currently lacking, resulting in many patients being classified as ‘other’. Moreover, many patients, including those with unclassified AF, will show overlapping mechanisms of AF according to this expert consensus.

A more precise classification of patients with AF that recognizes and accounts for the major disease mechanisms is needed. Characterizing the major health modifiers causing AF would provide the basis for tailored management, thereby yielding a maximum benefit and limiting adverse effects, in comparison with the current ‘one-size-fits-all’ therapeutic approach. For example, weight reduction can help to prevent AF recurrence and observational clinical data supported renin-angiotensin–aldosterone blockers in AF prevention schemes \(^{26,27}\), but subsequent large randomized trials did not demonstrate a clinical benefit in patients without an established indication for these substances \(^{30,31}\). Drugs with anti-inflammatory and antioxidative properties that were tested for the prevention of AF in several settings showed mixed outcomes \(^{33,32-35}\). Finding markers for the major disease mechanisms — or ‘health modifiers’ — causing AF in a given patient would enable some of these treatment modalities to be used successfully. Furthermore, if information on the individual drivers for AF were available, personalized, preventive, and therapeutic strategies against this major threat to healthy ageing could be developed \(^{36}\).

In this Consensus Statement, we critically assess how the current knowledge on the mechanisms of AF is identified in daily clinical practice, and the extent to which it is translated into therapeutic improvements. To bridge the current gap between basic knowledge and clinical management, we propose a series of steps to build a clinically useful, mechanistic classification of AF, and describe the starting point for developing a set of clinical markers for the major health modifiers causing AF.
in overweight patients with AF, and physical activity reduction might contribute to the prevention of AF in athletes. Specialized, nurse-led, AF clinics improve guideline adherence, and might also prove valuable in targeting risk factors, such as weight reduction, in identifying warning signs and symptoms, and by raising patient awareness of their disease. Upstream therapy might help to prevent AF in patients with heart failure. Notably, other less obvious major health modifiers that cause AF might not have yet been detected and, therefore, would not be treated via targeted therapy. Identifying the unknown factors, and implementing these into a health-modifier-based characterization in the future, could markedly improve patient care. This Consensus Statement should be considered a starting point.

**Defining patient health modifiers of AF**

A list of the major health modifiers causing AF, and of the corresponding clinical markers, would form a valid basis for stratified or personalized approaches to prevention and treatment (Box 2). We therefore propose, first, to identify the major health modifiers causing AF in patients in a systematic, concerted effort, and second, to generate a pathophysiological classification of patients with AF using the identified health modifiers.

We have chosen the term ‘health modifiers’ to refer to the major mechanisms driving AF in patients as they are meant to inform preventive and therapeutic approaches for AF. We selected the major mechanisms of AF on the basis of a group discussion and a review of the literature. The mechanisms described here are thought to be credible drivers for AF and to have a relevant effect in terms of pathogenic potential and prevalence in patients with AF, thus qualifying as candidates for the major health modifiers causing AF (Box 2). Clearly, this list is a starting point that needs scientific evaluation.

**Mechanisms of AF**

At the molecular and cellular levels, several drivers of AF have been identified, including ageing and atrial fibrosis, abnormal calcium homeostasis, sarcoplasmic reticulum calcium leak, ion-channel dysfunction (genetic or acquired), and autonomic dysfunction (for example, in athletes with elevated vagal tone). In addition, accumulating data support important contributions to the pathogenesis of AF of high levels of oxidative stress, infiltration of fat into the atria, as well as increases in the paracrine activity of atrial adipocytes and maladaptation owing to chronic kidney disease. All these mechanisms of AF (Box 1) have the potential to lead to atrial dysfunction (Fig. 1), although the involvement of each candidate for a major health modifier requires further validation.

**Atrial fibrosis and ageing**

AF leads to profound structural alterations, including an increased formation of extracellular matrix, deposition of fibrous material, and a marked change in gene expression patterns. Both AF itself and various clinical conditions associated with AF, such as inflammation, hypertension, cardiac hypertrophy, or mitral valve disease, can cause increased atrial fibrosis resulting in different fibrotic patterns. In addition, the ageing heart is constantly losing cardiomyocytes (estimated at 0.5–1.0% cardiomyocyte-loss per year), and fibrous tissue often forms in lieu of cardiomyocytes in older individuals. Impaired electrical coupling between myocytes within the epicardial layer, as well as between the epicardial layer and the endocardial bundle network, fosters three-dimensional, temporospatial conduction events (breakthroughs)35, thereby maintaining AF.

**Altered calcium homeostasis**

In the presence of AF, high atrial rates and early reactivation of cardiomyocytes elevate diastolic Ca²⁺ and intracellular Ca²⁺ storage. Adaptation to this new situation results in profound changes in the ion channels controlling Ca²⁺ reuptake and release by the sarcoplasmic reticulum. These changes persist for some time after the restoration of a normal sinus rhythm (for example, after cardioversion), rendering the recurrence of AF more likely. Increases in spontaneous electrical activity have been suggested to have a major role in abnormal intracellular Ca²⁺ handling in the genesis of AF. Although this theory has been challenged by reports demonstrating improved Ca²⁺ handling stability, and even Ca²⁺ silencing, after Af, increases in the sympathetic activity in the atrial tissue might still underlie the increase in the rate of ectopic activity during AF.

**Ion-channel dysfunction**

AF and other structural heart diseases result in changes in the expression, or in the post-translational regulation, of ion channels. These changes not only contribute to a shortening of atrial refractoriness, favouring re-entry, but also to prolongation of the atrial action potential and the triggered electrical activity. In addition to these adaptive changes in ion-channel regulation, the local milieu within atrial myocytes — influenced for example by shear stress, metabolic factors, atrial work load, or cellular age — also alters the expression and function of ion channels, possibly contributing to changes in refractoriness or in ectopic activity occurrence.
Genetic causes
AF has a strong familial component. Some pedigrees of early-onset AF are driven by mutations in ion-channel genes, which are also found in patients with inherited electrical diseases, such as the long QT syndrome, Brugada syndrome, and hypertrophic or arrhythmogenic right ventricular cardiomyopathy. Many inherited arrhythmia syndromes, which are characterized by mutations in cardiac ion channels, cause AF in structurally normal hearts. Patients with AF who have these mutations have been referred to as patients with ‘monogenic AF’. Early-onset AF is associated with common genetic variants (17 independent loci have been identified to date), with a hotspot for such variants on chromosome 4q25. The gene most closely located to the risk variants encodes the two-domain transcription factor, PITX2. Low expression levels of PITX2 mRNA induce complex left atrial gene expression changes, without apparent structural alterations, that predispose to AF. Thus, altered expression of atrial ion channels as a result of genetic alterations in the atria could be a common path by which subtle genetic changes predispose patients to AF, subsequently influencing the response to antiarrhythmic drugs.

Autonomic dysfunction
Atrial function is tightly regulated by the autonomic nervous system, which in turn can be an important factor that promotes the new onset of AF. Changes in sympathetic or parasympathetic tone alter the atrial action potential, as well as the refractory period, provoking depolarizations and triggered activity. One in three patients with paroxysmal AF, and up to 70% of younger patients, present with well-defined adrenergic or vagal triggers. Low-level vagal stimulation prevents AF by decreasing sympathetic and parasympathetic cardiac responsiveness in animal models susceptible to AF. High-intensity endurance training is an evolving risk factor underlying AF in middle-aged Europeans without overt structural heart disease, which can be mediated by an elevated parasympathetic tone, structural changes, or by changes in ion-channel expression. Similarly, AF in patients with obstructive sleep apnoea can be provoked by autonomic imbalance. Ganglionated plexi, heterogeneous sympathetic hyperinnervation, and nerve sprouting can contribute to AF in some patients.

Oxidative stress
Experimental studies have suggested that changes in the nitric oxide–redox balance of the atrial myocardium can...
Current approach to AF treatment
• Clinical risk scores
• AF pattern
• Acute presentation (often "random")

Mechanisms causing AF
Multiple have been described in great molecular detail, often in AF models

• Determine AF-related changes in human atrial tissue
e.g. ion-channel expression, fibrosis, infiltration of fat cells,
amyloidosis, complex genetics
• Determine the major clinical phenotypes predisposing patients to AF
e.g. concomitant cardiovascular conditions, genetic
and genomic predisposition, biometrics

Distill markers for the main mechanisms causing AF in patients
e.g. clinical parameters, ECG, blood

Validate indicators and quantify the relevance of each
health modifier in large, independent cohorts

New, stratified preventative and therapeutic approaches to
counter the major health modifiers causing AF in patients

Figure 2 | Disconnect between the mechanisms and the clinical treatment of AF,
and the proposed strategy to overcome it. Comparison of the current approach
to atrial fibrillation (AF) management, which is disconnected from the established insights
into AF pathophysiology, and the proposed approach to AF management in which the
major changes leading to AF will lead to a classification of patients with AF and provide
a basis for personalized prevention and management. ECG, electrocardiogram.

have an important role in the new onset and progression
of AF, by mediating the effects of systemic inflammation
on the atrial myocardium, and by acting on a number of relevant mechanisms. In humans, the
cytokine-stimulated gp91phox NADPH oxidase (Nox2)
is the main source of reactive oxygen species in isolated
atrial myocytes. Atrial Nox2 activity was significantly
increased shortly after AF induction in goats, and in atrial
samples from patients in sinus rhythm who developed AF
after cardiac surgery. These findings suggest that Nox2
inhibition with statins might prevent the new onset of
AF. However, the Statins In Cardiac Surgery trial has
provided good evidence against this assumption, suggesting
that either the level of Nox2 inhibition achieved by therapeu tic doses of statins in humans is not sufficient to
prevent postoperative AF, or that the association between
atrial Nox2 activity and AF is not causal.

Fat-cell infiltration and activation
The profound and swift effects of weight loss on AF cannot be explained by long-term cardiovascular protection. Obesity not only creates atrial fibrosis, but also increases epicardial fat. Furthermore, obesity leads to the infiltration of fat cells into the atrial tissue and to the activation of atrial fat cells, thus modifying atrial electrical function, providing a possible mechanism linking obesity and pericardial fat to AF. Therefore, epicardial adipose tissue could be an important health modifier for AF.

Chronic kidney disease
In large, unselected study populations, the risk of developing AF is increased in patients with a reduced estimated glomerular filtration rate of 30–59 ml/min/1.73 m² compared with those with normal renal function (HR 1.32), independently of other risk factors. Additionally, microalbuminuria and macroalbuminuria were associated with increased risk of AF. In patients with both chronic kidney disease and AF, the risk of stroke and the risk of bleeding are further increased compared with patients with AF only. However, neither vitamin K antagonist anticoagulant therapies, nor the non-vitamin-K antagonist oral anticoagulants, such as apixaban, dabigatran, edoxaban, or rivaroxaban, have been sufficiently tested in patients with severe chronic kidney disease to suggest safe use at present.

From atrial tissue to clinical markers
Several mechanisms that can cause AF have been identified and verified, but often in animal models of AF. This knowledge requires verification in patients, and translation into clinical markers that can be measured in clinical practice without needing access to atrial tissue. These mechanisms have plausible links to clinical conditions and to markers that can be used to identify patients at risk of AF, which provides good reason to explore putative markers for relevant health modifiers for AF. Therefore, a set of clinical markers to define the major health modifiers causing AF in specific patients can be developed, which subsequently will require validation in independent cohorts. Identification and validation of these markers could underpin new personalized approaches to AF prevention and therapy in the future, and ideally will be accessible in a wide variety of health-care settings. Such a set of markers would also accommodate the concept that several mechanisms can coexist and synergistically promote AF in individual patients.

A new classification of AF: a call to action
A major, direct benefit of a mechanistic classification of AF would be a personalized therapeutic approach on the basis of the most active processes in each patient, in addition to more accurate disease stratification, as well as better prevention of AF, and detection of silent AF. By identifying the leading health modifiers causing AF in individual patients, more effective therapies than those currently available could be selected at an earlier stage for primary preventive intervention or for the prevention of AF recurrence. Such personalized concepts will add to the existing practice of cardiovascular risk reduction. These interventions will comprise targeted treatment of reversible health modifiers, such as antifibrotic treatment in patients prone to atrial fibrosis, weight reduction in patients with atrial fat-cell infiltration, or selection of antiarrhythmic drugs on the basis of the atrial electrical function as determined by age or genetic predisposition. Although a complex network of arrhythmic processes is likely to culminate in AF, a balance between simplicity and the integration of the major mechanisms of AF is essential.
CONSENSUS STATEMENT

Figure 3 | Proposed roadmap for developing a classification of AF based on the major health modifiers leading to AF. Ideal steps towards a mechanistic classification of atrial fibrillation (AF) based on the major health modifiers that will help to progress from the current disconnect between AF mechanisms and management, to an approach to AF prevention and therapy that is informed by the different health modifiers causing AF in patients. The lower section of the flow chart illustrates some of the potential health benefits of a new classification of AF.


CONSENSUS STATEMENT


Acknowledgements

Authors involved in this work have received funding from the European Union’s Horizon 2020 research and innovation programme, under grant agreement No. 635193 [CATCH ME].

Author contributions


Competing interests statement

All authors except E.G., C.A., I.B., D.C., WWLC., S.M., M.F.S., T.S., and A.W. declare competing interests. See the article online for full details of the relationships.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© 2015 Macmillan Publishers Limited. All rights reserved